Sponsored information from

Primary care Action Interactive Cases

Return to homepage 

Marianna, 49

Marianna is a 49-year-old female shift worker who works as a nurse.

She visits you to discuss her weight.

Patient history

  • Lifetime weight issues
  • Previous weight-loss attempts have been varied; some have worked temporarily
  • Non-smoker
  • Moderate alcohol intake
  • Struggles to maintain an exercise schedule
  • Worried about her weight and its impact on her health and ability to function
  • Aware of possible management options

Current clinical measurements

  • Current day BMI 32 kg/m2 (BMI 6 months prior: 31 kg/m2)
  • HbA1c 5.4% (35 mmol/mol)
  • BP 112/78 mmHg
  • Total cholesterol 4.0 mmol/L (155 mg/dL)
  • LDL cholesterol 2.3 mmol/L (89 mg/dL)
  • ALT 12 U/L and AST 21 U/L
  • Additional information:
  • eGFR 91 mL/min/1.73 m2

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BP: blood pressure; eGFR: estimated glomerular filtration rate; FIB-4: Fibrosis-4 index; GLP-1 RA: glucagon-like peptide-1 receptor agonist; LDL: low-density lipoprotein

Hide medical notes 
Clinical data 

This is a fictional case study. The model is not a real patient and the situation shown does not reflect the model's experience.

References
  1. Vieira Barbosa J, Milligan S et al. Fibrosis-4 index as an independent predictor of mortality and liver-related outcomes in NAFLD. Hepatol Commun 2022;6(4):765-779
  2. Loomba R, Adams L A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. Hepatology 2019;70(6):1885-1888
  3. Sterling R K, Lissen E et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006;43(6):1317-1325
  4. Burki T. European Commission classifies obesity as a chronic disease. Lancet Diabetes Endocrinol 2021;9(7):418
  5. Bray G A, Kim K K, Wilding J P H. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 2017;18(7):715-723
  6. National Institute for Health and Care Excellence (NICE). NICE clinical guideline 189. Obesity: identification, assessment and management, November 2014 (last updated September 2022). Available at: nice.org.uk. Accessed August 2023
  7. Burridge K, Christensen S M et al. Obesity history, physical exam, laboratory, body composition, and energy expenditure: an Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. Obesity Pillars 2022;1:100007
  8. Steelman G M, Westman E C (eds). Obesity: evaluation and treatment essentials, 2nd edn. CRC Press, 2016.
  9. Stephenson J, Smith C M et al. The association between obesity and quality of life: a retrospective analysis of a large-scale population-based cohort study. BMC Public Health 2021;21(1):1990
  10. Yumuk V, Tsigos C et al. European guidelines for obesity management in adults. Obes Facts 2015;8(6):402-424
  11. Garvey W T, Mechanick J I et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocrine Practice 2016;22:1-203
  12. Gregg E W, Jakicic J M et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol 2016;4(11):913-921
  13. Lean M E, Leslie W S et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018;391(10120):541-551
  14. Benraouane F, Litwin S E. Reductions in cardiovascular risk after bariatric surgery. Curr Opin Cardiol 2011;26(6):555-561
  15. Sundström J, Bruze G et al. Weight loss and heart failure: a nationwide study of gastric bypass surgery versus intensive lifestyle treatment. Circulation 2017;135(17):1577-1585
  16. Colin I M, Gerard K M. Once-weekly 2.4 mg semaglutide for weight management in obesity: a game changer? touchREV Endocrinol 2022;18(1):35-42
  17. Guidelines in practice. Top tips: talking about weight. Available at: guidelinesinpractice.co.uk. Accessed August 2023
  18. Albury C, Strain W D et al. The importance of language in engagement between health-care professionals and people living with obesity: a joint consensus statement. Lancet Diabetes Endocrinol 2020;8(5):447-455
  19. Wharton S, Lau D C W et al. Obesity in adults: a clinical practice guideline. CMAJ 2020;192(31):E875-e891
  20. Eisenberg D, Shikora S A et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): indications for metabolic and bariatric surgery. Surg Obes Relat Dis 2022;18(12):1345-1356
  21. Liraglutide Summary of Product Characteristics
  22. Naltrexone hydrochloride and bupropion hydrochloride Summary of Product Characteristics
  23. Orlistat Summary of Product Characteristics
  24. Semaglutide Summary of Product Characteristics
  25. Pedersen S D, Manjoo P, Wharton S. Canadian adult obesity clinical practice guidelines: pharmacotherapy for obesity management. Available at: obesitycanada.ca. Accessed August 2023